Still, NVTA stock is up by nearly 120% in the past five trading days. Cathie Wood’s Ark Invest reported purchasing 812,943 shares the day before earnings through two exchange-traded funds (ETFs). Before this purchase, Ark last bought shares on June 15.
For Q2, this genetics testing company posted revenue of $136.6 million, up more than 17% year-over-year (YOY). Revenue fell short of the Zacks consensus estimate by just 0.62%; Invitae has only beaten the consensus estimate once in the past four quarters. Unlike revenue, however, adjusted earnings per share (EPS) tallied in at a loss of 68 cents, beating the estimated loss of 74 cents. As of Q2, Invitae had 20,217 active healthcare provider accounts, up about 25% YOY.
As far as full-year revenue guidance goes, the company expects a “low double-digit growth rate.” Management says growth may pick up beyond 2023, with revenue expected to grow between 15% and 25% in the following years. On top of that, the company forecasts cash burn of between $600 million and $650 million this year.
NVTA Stock: Cathie Wood Buys Shares
After the Ark purchases, NVTA stock is now the 45th largest holding across all Ark ETFs out of total of 51. In the ARK Genomic Revolution ETF (BATS:ARKG), the stock is the 40th largest holding out of 49 total. It is also the 33rd largest holding of 35 total in the ARK Innovation ETF (NYSEARCA:ARKK).
Ark reportedly holds a total of 25.14 million shares, with the dollar value of that stake worth $62.73 million according to Cathie’s Ark. However, the firm is sitting on a massive loss, as the cost basis for the stake is $12.30 and $13.49 in the two ETFs that own NVTA stock.
At a closer look, Invitae’s earnings don’t seem to explain yesterday’s massive move. Instead, a short squeeze may be the culprit. As the price of NVTA rose higher yesterday, more shorts capitulated in order to avoid a loss. When short sellers capitulate, they must buy shares of the underlying company.
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
On the date of publication, Eddie Pan did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.